A phase II clinical trial to study the use of cabozantinib (cabo) in patients with hepatocellular carcinoma (HCC) post immunotherapy treatment.
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
cabozantinib,hepatocellular carcinoma,immunotherapy treatment
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要